Skip to content
Inciteful Med

Getting an Accurate MELAS Diagnosis

Last updated:

MELAS is diagnosed using four main pillars: clinical symptoms, elevated lactate levels, specific MRI brain imaging patterns, and muscle biopsies showing ragged red fibers. Genetic testing is often more accurate using urine or muscle samples rather than blood due to variable mutation levels in different tissues.

Key Takeaways

  • • MELAS is diagnosed through a combination of clinical symptoms, elevated lactate, advanced brain imaging, and muscle biopsies.
  • • Stroke-like episodes in MELAS look different on MRI scans than typical strokes, often crossing vascular boundaries.
  • • MR Spectroscopy (MRS) can detect a 'lactate peak' in the brain, which is a key indicator of mitochondrial dysfunction.
  • • Muscle biopsies in MELAS patients often reveal 'ragged red fibers' and severe structural damage to mitochondria.
  • • Genetic testing for the m.3243A>G mutation is often more accurate when performed on urine or muscle samples rather than blood.

Diagnosing MELAS can be a complex “detective process” because the symptoms often mimic other conditions, such as typical strokes or viral brain infections (like herpes encephalitis) [1][2]. Because it is a multisystem disease, doctors rely on four main “pillars” of evidence to confirm the diagnosis.

Pillar 1: Clinical Presentation

The first clue is often the combination of symptoms. Doctors look for the classic “triad” that gives MELAS its name: brain/muscle involvement (Encephalomyopathy), high lactic acid (Lactic Acidosis), and Stroke-like episodes [3]. They also look for “red flags” like early-onset hearing loss, diabetes, or short stature [4][5].

Pillar 2: Biochemical Markers (Lactate & Pyruvate)

When mitochondria fail to produce energy using oxygen, the body switches to a backup system that creates lactic acid as a byproduct [6].

  • Elevated Lactate: High levels of lactate in the blood or cerebrospinal fluid (CSF) are a hallmark of MELAS [7].
  • Lactate/Pyruvate Ratio: Doctors often look at the ratio between lactate and pyruvate. A high ratio suggests the “engine” of the cell is struggling specifically with oxidative metabolism [8].

Pillar 3: Advanced Imaging (MRI & MRS)

Standard MRIs look at the structure of the brain, but specialized scans look at its function and chemistry.

  • Non-Vascular Territories: In a typical stroke, the damage follows the path of a specific artery. In MELAS, the “stroke-like” lesions often cross these boundaries and “migrate” or move over time [9][10].
  • ADC Map: On a specific MRI setting called the ADC map, MELAS lesions often show a normal or increased signal, indicating vasogenic edema. In a typical stroke, this signal is usually reduced [9][11].
  • MR Spectroscopy (MRS): This tool measures brain chemistry. In MELAS, an MRS scan will show a “lactate peak”—a spike in lactic acid—even in parts of the brain that look normal on a regular MRI [9][12].

Pillar 4: Muscle Biopsy Findings

If a genetic test is unclear, a doctor may perform a muscle biopsy to look for physical evidence of mitochondrial damage.

  • Ragged Red Fibers (RRFs): Under a specific stain (Gomori trichrome), damaged muscle fibers appear “ragged” and bright red [13][14]. This happens because the cell is desperately trying to overcompensate by making more (but broken) mitochondria [3][15].
  • Paracrystalline Inclusions: Using an electron microscope, doctors may see tiny, “parking lot-like” crystals inside the mitochondria, which are a sign of severe structural damage [14][16].

The Genetic Testing Trap

The most common cause of MELAS is the m.3243A>G mutation [17]. However, getting a “negative” result from a blood test does not always mean you don’t have the disease.

  • Heteroplasmy: Because you can have different amounts of mutated DNA in different tissues, the level in your blood might be very low (especially as you get older), while the level in your brain, muscles, or kidneys is high [18][19].
  • Urine vs. Blood: Testing urine (urothelial cells) or a muscle sample is often more accurate for diagnosing MELAS because the mutation level is typically higher in those tissues than in the blood [20][21].

Diagnostic Completeness Checklist

If you are auditing your own or your child’s medical records, look for these specific mentions:

  • [ ] Lactate/Pyruvate levels (elevated in blood or CSF) [7].
  • [ ] Brain MRI report noting if lesions “violate vascular territories” [9].
  • [ ] MR Spectroscopy (MRS) report mentioning a “lactate peak” [9].
  • [ ] Genetic test results for the m.3243A>G mutation (and if it was blood or urine) [18].
  • [ ] Muscle Biopsy (if done) mentioning “Ragged Red Fibers” [13].

Once diagnosed, it is critical to move on to Standard of Care: Managing Acute Episodes and Daily Health.

Frequently Asked Questions

Why might a blood test be negative for MELAS if I actually have it?
Because of a concept called heteroplasmy, the mutated DNA can be at very low levels in the blood while being high in other tissues like the brain or muscles. Testing a urine or muscle sample is often more accurate for finding the MELAS mutation.
What does a lactate peak on an MR Spectroscopy (MRS) mean?
A lactate peak indicates a spike in lactic acid in the brain. In MELAS, this peak can appear on an MRS scan even in areas of the brain that look normal on a standard MRI, helping doctors distinguish it from a typical stroke.
How do MELAS stroke-like episodes look different on an MRI compared to a regular stroke?
Unlike a typical stroke that follows the path of a specific blood vessel, MELAS lesions often cross these vascular boundaries and can migrate over time. They also show a different type of swelling on an ADC map MRI.
What are ragged red fibers in a muscle biopsy?
Ragged red fibers are damaged muscle cells that appear bright red and jagged under a microscope. They occur because the cell is desperately trying to overcompensate for energy failure by making more defective mitochondria.
What is the classic triad of MELAS symptoms?
The classic triad consists of brain and muscle involvement (encephalomyopathy), high lactic acid levels in the blood or spinal fluid (lactic acidosis), and stroke-like episodes. Doctors also look for red flags like early-onset hearing loss or diabetes.

Questions for Your Doctor

  • • Why was my (or my child’s) genetic test done on blood instead of urine, and should we re-test to be sure?
  • • Did the MRI report mention if the lesions followed vascular territories or if the ADC signal was normal/increased?
  • • Was there a lactate peak on the MR Spectroscopy (MRS) in areas of the brain that looked normal on the regular MRI?
  • • If we do a muscle biopsy, will the pathologist be specifically looking for Ragged Red Fibers and paracrystalline inclusions?
  • • How do our lactate and pyruvate levels compare to what you'd expect in a typical stroke vs. MELAS?

Questions for You

  • • Has anyone in my mother’s side of the family had 'atypical' strokes, early hearing loss, or diabetes?
  • • When I (or my child) had a 'stroke-like' episode, was it preceded by a seizure or a severe migraine?
  • • Do I have copies of my MRI images and pathology reports to show a mitochondrial specialist for a second opinion?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Adult-onset mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome with progressive sensorineural hearing loss: A case report.

    Trang TM, Chien PC, Dung BT, et al.

    Radiology case reports 2021; (16(7)):1865-1869 doi:10.1016/j.radcr.2021.04.049.

    PMID: 34093932
  2. 2

    Adult onset MELAS Syndrome Presenting as A Mimic of Herpes Simplex Encephalitis.

    Chen WT, Lin YS, Wang YF, Fuh JL

    Acta neurologica Taiwanica 2019; (28(2)()):46-51.

    PMID: 31867706
  3. 3

    MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

    El-Hattab AW, Adesina AM, Jones J, Scaglia F

    Molecular genetics and metabolism 2015; (116(1-2)):4-12.

    PMID: 26095523
  4. 4

    Cochlear Implantation in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome: Case Presentation.

    Crundwell G, Kullar P, Bance M

    The journal of international advanced otology 2022; (18(1)):71-73 doi:10.5152/iao.2022.21316.

    PMID: 35193849
  5. 5

    Approach to the Patient - Mitochondrial Diabetes: Contemporary Cases and Precision Medicine Approach.

    Oppenheimer KR, Himelhoch NT, McCullough ME, et al.

    The Journal of clinical endocrinology and metabolism 2025; doi:10.1210/clinem/dgaf698.

    PMID: 41472381
  6. 6

    The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model.

    Frey S, Geffroy G, Desquiret-Dumas V, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(1)):284-291 doi:10.1016/j.bbadis.2016.10.028.

    PMID: 27815040
  7. 7

    Acute Management of Neurological Events in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome: A Case Report.

    Aladashvili Z, Rodriguez TB, Izquierdo-Pretel G

    Cureus 2025; (17(5)):e83959 doi:10.7759/cureus.83959.

    PMID: 40502899
  8. 8

    Application of molecular imaging combined with genetic screening in diagnosing MELAS, diabetes and recurrent pancreatitis.

    Zhiping W, Quwen L, Hai Z, et al.

    Folia neuropathologica 2016; (54(1)):66-71 doi:10.5114/fn.2016.58917.

    PMID: 27179223
  9. 9

    Migratory stroke-like lesions in a case of adult-onset mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome and a review of imaging findings.

    Cai SS, von Coelln R, Kouo TJ

    Radiology case reports 2016; (11(4)):425-429 doi:10.1016/j.radcr.2016.09.003.

    PMID: 27920873
  10. 10

    Diagnosis of adult-onset MELAS syndrome in a 63-year-old patient with suspected recurrent strokes - a case report.

    Sinnecker T, Andelova M, Mayr M, et al.

    BMC neurology 2019; (19(1)):91 doi:10.1186/s12883-019-1306-6.

    PMID: 31068171
  11. 11

    Simultaneous 18F-FDG PET/MRI Assists Diagnosis of a Rare Disease, MELAS.

    Liu F, Ruan W, Wang Y, Lan X

    Clinical nuclear medicine 2019; (44(1)):81-82 doi:10.1097/RLU.0000000000002344.

    PMID: 30371584
  12. 12

    Multiparametric MRI detection of cerebral metabolism: a tool for early differentiation between MELAS and ischemic cerebral infarction.

    Yang X, Xu Y, Zhang S, et al.

    Quantitative imaging in medicine and surgery 2025; (15(10)):9466-9478 doi:10.21037/qims-24-2396.

    PMID: 41081123
  13. 13

    Immunonutrition for the acute treatment of MELAS syndrome.

    Pérez-Cruz E, González-Rivera C, Valencia-Olvera LDCG

    Endocrinologia, diabetes y nutricion 2021; doi:10.1016/j.endinu.2021.03.004.

    PMID: 34210633
  14. 14

    Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome: a case report.

    Ru YX, Ying L, Dong SX, et al.

    Ultrastructural pathology 2023; (47(3)):227-235 doi:10.1080/01913123.2023.2184892.

    PMID: 36871223
  15. 15

    A novel tRNASer(AGY) 12244G > a variant impairs mitochondrial function and presents with classical MELAS phenotype.

    Zhuang X, Wang J, Wang J, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(3)):264 doi:10.1007/s10072-026-08875-y.

    PMID: 41692888
  16. 16

    [Ultrastructural and clinical findings of mitochondrial encephalomyopathy:report of 27 cases].

    Zhang Q, Sun YL, Zhang CP, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2019; (48(4)):298-302 doi:10.3760/cma.j.issn.0529-5807.2019.04.007.

    PMID: 30955266
  17. 17

    Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic.

    Pröbstel AK, Schaller A, Lieb J, et al.

    Neurology. Genetics 2016; (2(6)):e121 doi:10.1212/NXG.0000000000000121.

    PMID: 27878137
  18. 18

    Droplet digital polymerase chain reaction to measure heteroplasmic m.3243A>G mitochondrial mutations.

    Matsumoto S, Uchiumi T, Noda N, et al.

    Laboratory medicine 2024; (55(2)):227-233 doi:10.1093/labmed/lmad063.

    PMID: 37478467
  19. 19

    mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.

    Grady JP, Pickett SJ, Ng YS, et al.

    EMBO molecular medicine 2018; (10(6)) doi:10.15252/emmm.201708262.

    PMID: 29735722
  20. 20

    A case with short stature and proteinuria: atypical presentation of a family with m.3243A>G mutation.

    Büyükyılmaz G, İnözü M, Çavdarlı B

    The Turkish journal of pediatrics 2024; (66(4)):490-498 doi:10.24953/turkjpediatr.2024.4702.

    PMID: 39387423
  21. 21

    MELAS Syndrome and Kidney Disease Without Fanconi Syndrome or Proteinuria: A Case Report.

    Rudnicki M, Mayr JA, Zschocke J, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(6)):949-953 doi:10.1053/j.ajkd.2016.06.027.

    PMID: 27683045

This page explains the diagnostic process for MELAS for educational purposes only. Always consult a mitochondrial specialist or neurologist to interpret your specific test results and imaging scans.

Stay up to date

Get notified when new research about MELAS is published.

No spam. Unsubscribe anytime.